COMPARISON OF GENEXPERT® PROBE MISSING IN HOTSPOT RRDR OF RPOB GENE AMONG PRIMARY AND ACQUIRED DRUG RESISTANT CASES OF PULMONARY TUBERCULOSIS

MK MUNIR; S SHAMIM; S REHMAN; A HANIF; MS SAEED

doi:10.54112/bcsrj.v2022i1.165

Authors

MK MUNIR Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore Pakistan/HRI-NIH TB Research Centre KEMU/Mayo Hospital Lahore, Pakistan
S SHAMIM Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore Pakistan
S REHMAN HRI-NIH TB Research Centre KEMU/Mayo Hospital Lahore, Pakistan
A HANIF Department of Pulmonology King Edward Medical University Lahore, Pakistan
MS SAEED Department of Pulmonology King Edward Medical University Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2022i1.165

Keywords:

Genotyping, Mycobacterium tuberculosis, MTB complex, Epidemiology, Diagnosis

Abstract

There are differences in probe pattern missing in rifampicin resistance determining region of rpoB gene among primary and acquired resistant TB cases. This study aimed to observe the Xpert® MTB RIF Assay presenting probe missing in Hotspot RRDR of rpoB Gene among primary and acquired drug-resistant cases of pulmonary tuberculosis in a tertiary care setting of Lahore. This comparative cross-sectional work was undertaken at The University of Lahore in cooperation with the Department of Pulmonology and HRI-NIH TB Research Centre KEMU
Lahore. Confirmed TB patients being sent for Xpert® MTB RIF Assay were the target population in this study. Based on previous TB treatment history, patients were divided into primary and acquired drug-resistant TB cases. Samples were subjected to Xpert® MTB RIF Assay, and any probes missing, i.e., probes A, B, C, D or E, were observed. Data from a total of 170 cases were finalized for analysis consisting of 84(49.4%) acquired TB cases and 86(50.6%)
primary TB cases. A total of 90(52.9%) male and 80(47.1%) females were enrolled. The mean age of patients was 35.45±16.11 years. The proportion of missing probe E (78.2%) remained at the topmost, followed by none of the probes missing at 8.3%, probe A at 5.3%, probe C at 3.5%, probe B at 2.9% and probe D at 1.8%. There are variations in frequencies of probe missing in RDRR regions of rpoB genes among rifampicin-resistant cases of primary and
acquired TB. A high frequency of no missing probes among primary resistant was found.

Downloads

Download data is not yet available.

References

Alemu, A., Tadesse, M., Seid, G., Mollalign, H., Eshetu, K., Sinshaw, W., Abebaw, Y., Amare, M., Dagne, B., and Diriba, G. (2020). Does Xpert® MTB/RIF assay give rifampicin resistance results without identified mutation? Review of cases from Addis Ababa, Ethiopia. BMC Infectious Diseases 20, 1-6.

Bayot, M. L., Mirza, T. M., and Sharma, S. Acid fast bacteria. [Update August 2021, Cited September 2022] Available from: [https://www.ncbi.nlm.nih.gov/books/NBK537121/].

Bussi, C., and Gutierrez, M. G. (2019). Mycobacterium tuberculosis infection of host cells in space and time. FEMS Microbiol Rev 43, 341-361.

Kanade, S., Nataraj, G., Mehta, P., and Shah, D. (2019). Pattern of missing probes in rifampicin resistant TB by Xpert MTB/RIF assay at a tertiary care centre in Mumbai. Indian Journal of Tuberculosis 66, 139-143.

Kashif Munir, M., Ali, I., Sattar Sheikh, A., Malik, A., Hanif, A., Rehman, S., Khaliq Munir, S., and Ali, Q. (2021). Efficacy of GeneXpert in Diagnosing Smear Negative Pulmonary Tuberculosis and Comparison to Culture. J Pharm Res Int 33, 6-12.

Kesarwani, R., Pandey, A., Misra, A., and Singh, A. K. (2004). Polymerase chain reaction (PCR): Its comparison with conventional techniques for diagnosis of extra-pulmonary tubercular diseases. Indian J Sug. 66, 84-88.

Kumar, V., Bala, M., Kanga, A., and Gautam, N. (2020). Identification of Missing Probes in rpoB gene in Rifampicin Resistant PTB and EPTB Cases Using Xpert MTB/RIF Assay in Sirmaur, Himachal Pradesh. The Journal of the Association of Physicians of India 68, 33-36.

Lawn, S. D., and Nicol, M. P. (2011). Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future microbiology 6, 1067-1082.

Moreno-Molina, M., Shubladze, N., Khurtsilava, I., Avaliani, Z., Bablishvili, N., Torres-Puente, M., Villamayor, L., Gabrielian, A., Rosenthal, A., and Vilaplana, C. (2021). Genomic analyses of Mycobacterium tuberculosis from human lung resections reveal a high frequency of polyclonal infections. Nature communications 12, 1-11.

Patterson, B., Morrow, C. D., Kohls, D., Deignan, C., Ginsburg, S., and Wood, R. (2017). Mapping sites of high TB transmission risk: integrating the shared air and social behaviour of TB cases and adolescents in a South African township. Science of The Total Environment 583, 97-103.

Rahman, A., Sahrin, M., Afrin, S., Earley, K., Ahmed, S., Rahman, S. M., and Banu, S. (2016). Comparison of Xpert MTB/RIF assay and GenoType MTBDR plus DNA probes for detection of mutations associated with rifampicin resistance in Mycobacterium tuberculosis. PLoS One 11, e0152694.

Welekidan, L. N., Yimer, S. A., Skjerve, E., Dejene, T. A., Homberset, H., Tønjum, T., and Brynildsrud, O. (2021). Whole Genome Sequencing of Drug Resistant and Drug Susceptible Mycobacterium tuberculosis Isolates From Tigray Region, Ethiopia. Front Microbiol 12, https://doi.org/10.3389/fmicb.2021.743198.

WHO Global tuberculosis report 2020. Geneva. Licence: CC BY-NC-SA 3.0 IGO. [Updated 2021, Cited 2022] Available from: [https://www.who.int/publications/i/item/9789240013131].

WHO World Health Organization. Global tuberculosis report 2021: Geneva: Licence: CC BY-NC-SA 3.0 IGO. [Updated 2022, Cited 2022] Availble from: [https://creativecommons.org/licenses/by-nc-sa/3.0/igo].